<p>Fmr LLC 在最近向证券交易委员会提交的文件中表示，在第四季度减少了对 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - 免费报告) 的持股比例，降幅为 0.4%。该基金在此期间出售了 45,207 股后，持有该生物制药公司 11,076,445 股股票。Fmr LLC 在最近的报告期末持有 Intra-Cellular Therapies 10.42% 的股份，价值 925,105,000 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 01/13 - 01/17</li>
</ul>
<p>其他一些对冲基金也最近调整了对 ITCI 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Intra-Cellular Therapies 的持股提高了 1.0%。先锋集团目前持有该生物制药公司 9,721,360 股股票，价值 811,928,000 美元，此前在上个季度又购买了 93,107 股。挪威银行（Norges Bank）在第四季度新购入了 Intra-Cellular Therapies 的股份，价值约 268,347,000 美元。州街公司（State Street Corp）在第三季度将其在 Intra-Cellular Therapies 的股份提高了 3.1%。州街公司目前持有该生物制药公司 1,858,915 股股票，价值 136,017,000 美元，此前在上个季度又购买了 56,664 股。富兰克林资源公司（Franklin Resources Inc.）在第四季度将其在 Intra-Cellular Therapies 的持股提高了 1.3%。富兰克林资源公司目前持有该生物制药公司 1,776,880 股股票，价值 148,405,000 美元，此前在此期间又购买了 23,594 股。最后，Geode Capital Management LLC 在第四季度将其在 Intra-Cellular Therapies 的持股提高了 0.5%。Geode Capital Management LLC 目前持有该生物制药公司 1,716,829 股股票，价值 143,434,000 美元，此前在上个季度又收购了 8,528 股。对冲基金和其他机构投资者持有该公司 92.33% 的股份。</p>
<h2>Intra-Cellular Therapies 股票表现</h2>
<p>ITCI 股票周二开盘价为 131.87 美元。Intra-Cellular Therapies, Inc. 的 12 个月最低价为 64.09 美元，最高价为 131.98 美元。该股票的市值为 140.5 亿美元，市盈率为-151.57，贝塔值为 0.69。该股票的 50 日移动平均线为 129.71 美元，200 日移动平均线为 102.19 美元。</p>
<ul>
<li>强生股票是否准备回报长期持有者？</li>
</ul>
<p>Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 最近一次发布财报是在 2 月 21 日，生物制药公司报告该季度每股收益（EPS）为-0.16，低于市场共识预期的-0.08，差距为-0.08。Intra-Cellular Therapies 的股本回报率为-9.93%，净利润率为-14.07%。该公司该季度的收入为 1.9922 亿美元，而分析师预期为 2.0508 亿美元。研究分析师平均预测 Intra-Cellular Therapies, Inc. 在当前财年将发布-0.64 的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>一些股票研究分析师对 ITCI 股票发表了看法。Cantor Fitzgerald 在 4 月 2 日的报告中重申了 “中性” 评级，并对 Intra-Cellular Therapies 的股票设定了 132.00 美元的目标价。加拿大皇家银行（Royal Bank of Canada）在 1 月 22 日的研究报告中重申了 “行业表现” 评级，并将 Intra-Cellular Therapies 的目标价上调至 132.00 美元（之前为 108.00 美元）。Needham &amp; Company LLC 在 2 月 21 日的研究报告中重申了对 Intra-Cellular Therapies 的 “持有” 评级。StockNews.com 在周六对 Intra-Cellular Therapies 开始覆盖，并对该股票给予 “持有” 评级。最后，Baird R W 在 1 月 13 日的报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。共有 11 位研究分析师对该股票给予 “持有” 评级，5 位分析师给予该公司 “买入” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，共识目标价为 106.23 美元。</p>
<ul>
<li>百时美施贵宝的大手笔收购：18.1 亿美元的两笔生物科技交易</li>
</ul>
<p><strong>获取我们关于 Intra-Cellular Therapies 的最新股票报告</strong></p>
<h2>Intra-Cellular Therapies 公司简介</h2>
<p>（免费报告）</p>
<p>Intra-Cellular Therapies, Inc. 是一家生物制药公司，专注于小分子药物的发现、临床开发和商业化，这些药物主要针对神经精神和神经系统疾病的医疗需求，通过靶向中枢神经系统（CNS）中的细胞内信号机制。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Intra-Cellular Therapies</li>
<li>股票中的缺口上涨意味着什么？如何操作缺口</li>
<li>期权活动指向 Palantir 股票的更多波动性</li>
<li>选举股票：选举如何影响股市</li>
<li>NVIDIA 股票：被低估，超卖——能跌到多低？</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>MicroStrategy 在第一季度看到内部买卖活动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Intra-Cellular Therapies 吗？</h2>
<p>在考虑 Intra-Cellular Therapies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Intra-Cellular Therapies 并不在名单上。</p>
<p>虽然 Intra-Cellular Therapies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ITCI

<p>Fmr LLC 在第四季度将其在 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) 的持股减少了 0.4%，目前持有 11,076,445 股，价值 9.251 亿美元。其他对冲基金，包括先锋集团和挪威银行，也调整了他们的持仓。ITCI 股票开盘价为 131.87 美元，12 个月的价格区间为 64.09 美元至 131.98 美元。该公司报告每股亏损 0.16 美元，未达到预期，收入为 1.9922 亿美元。分析师维持 “持有” 评级，普遍目标价为 106.23 美元</p>

<p>Fmr LLC lessened its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 11,076,445 shares of the biopharmaceutical company's stock after selling 45,207 shares during the period. Fmr LLC owned 10.42% of Intra-Cellular Therapies worth $925,105,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Fmr LLC 在最近向证券交易委员会提交的文件中表示，在第四季度减少了对 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - 免费报告) 的持股比例，降幅为 0.4%。该基金在此期间出售了 45,207 股后，持有该生物制药公司 11,076,445 股股票。Fmr LLC 在最近的报告期末持有 Intra-Cellular Therapies 10.42% 的股份，价值 925,105,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 01/13 - 01/17</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 01/13 - 01/17</li>
</ul>
</div><p>A number of other hedge funds have also recently modified their holdings of ITCI. Vanguard Group Inc. raised its holdings in Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company's stock worth $811,928,000 after purchasing an additional 93,107 shares in the last quarter. Norges Bank bought a new position in Intra-Cellular Therapies in the fourth quarter worth about $268,347,000. State Street Corp raised its stake in Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after buying an additional 56,664 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Intra-Cellular Therapies by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 1,776,880 shares of the biopharmaceutical company's stock worth $148,405,000 after buying an additional 23,594 shares during the period. Finally, Geode Capital Management LLC boosted its position in Intra-Cellular Therapies by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,716,829 shares of the biopharmaceutical company's stock valued at $143,434,000 after acquiring an additional 8,528 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金也最近调整了对 ITCI 的持股。先锋集团（Vanguard Group Inc.）在第四季度将其在 Intra-Cellular Therapies 的持股提高了 1.0%。先锋集团目前持有该生物制药公司 9,721,360 股股票，价值 811,928,000 美元，此前在上个季度又购买了 93,107 股。挪威银行（Norges Bank）在第四季度新购入了 Intra-Cellular Therapies 的股份，价值约 268,347,000 美元。州街公司（State Street Corp）在第三季度将其在 Intra-Cellular Therapies 的股份提高了 3.1%。州街公司目前持有该生物制药公司 1,858,915 股股票，价值 136,017,000 美元，此前在上个季度又购买了 56,664 股。富兰克林资源公司（Franklin Resources Inc.）在第四季度将其在 Intra-Cellular Therapies 的持股提高了 1.3%。富兰克林资源公司目前持有该生物制药公司 1,776,880 股股票，价值 148,405,000 美元，此前在此期间又购买了 23,594 股。最后，Geode Capital Management LLC 在第四季度将其在 Intra-Cellular Therapies 的持股提高了 0.5%。Geode Capital Management LLC 目前持有该生物制药公司 1,716,829 股股票，价值 143,434,000 美元，此前在上个季度又收购了 8,528 股。对冲基金和其他机构投资者持有该公司 92.33% 的股份。</p>
</div><h2>Intra-Cellular Therapies Stock Performance</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 股票表现</h2>
</div><p>Shares of ITCI stock opened at $131.87 on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock has a 50 day moving average of $129.71 and a 200 day moving average of $102.19.</p>
<div class="lb-trans"><p>ITCI 股票周二开盘价为 131.87 美元。Intra-Cellular Therapies, Inc. 的 12 个月最低价为 64.09 美元，最高价为 131.98 美元。该股票的市值为 140.5 亿美元，市盈率为-151.57，贝塔值为 0.69。该股票的 50 日移动平均线为 129.71 美元，200 日移动平均线为 102.19 美元。</p>
</div><ul>
<li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li>
</ul>
<div class="lb-trans"><ul>
<li>强生股票是否准备回报长期持有者？</li>
</ul>
</div><p>Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies (NASDAQ:ITCI - 获取免费报告) 最近一次发布财报是在 2 月 21 日，生物制药公司报告该季度每股收益（EPS）为-0.16，低于市场共识预期的-0.08，差距为-0.08。Intra-Cellular Therapies 的股本回报率为-9.93%，净利润率为-14.07%。该公司该季度的收入为 1.9922 亿美元，而分析师预期为 2.0508 亿美元。研究分析师平均预测 Intra-Cellular Therapies, Inc. 在当前财年将发布-0.64 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts have weighed in on ITCI shares. Cantor Fitzgerald restated a &#34;neutral&#34; rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Royal Bank of Canada restated a &#34;sector perform&#34; rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Saturday. They issued a &#34;hold&#34; rating on the stock. Finally, Baird R W downgraded Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of &#34;Hold&#34; and a consensus price target of $106.23.</p>
<div class="lb-trans"><p>一些股票研究分析师对 ITCI 股票发表了看法。Cantor Fitzgerald 在 4 月 2 日的报告中重申了 “中性” 评级，并对 Intra-Cellular Therapies 的股票设定了 132.00 美元的目标价。加拿大皇家银行（Royal Bank of Canada）在 1 月 22 日的研究报告中重申了 “行业表现” 评级，并将 Intra-Cellular Therapies 的目标价上调至 132.00 美元（之前为 108.00 美元）。Needham &amp; Company LLC 在 2 月 21 日的研究报告中重申了对 Intra-Cellular Therapies 的 “持有” 评级。StockNews.com 在周六对 Intra-Cellular Therapies 开始覆盖，并对该股票给予 “持有” 评级。最后，Baird R W 在 1 月 13 日的报告中将 Intra-Cellular Therapies 的评级从 “强力买入” 下调至 “持有”。共有 11 位研究分析师对该股票给予 “持有” 评级，5 位分析师给予该公司 “买入” 评级。根据 MarketBeat 的数据，该股票的平均评级为 “持有”，共识目标价为 106.23 美元。</p>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的大手笔收购：18.1 亿美元的两笔生物科技交易</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on Intra-Cellular Therapies</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Intra-Cellular Therapies 的最新股票报告</strong></p>
</div><h2>Intra-Cellular Therapies Company Profile</h2>
<div class="lb-trans"><h2>Intra-Cellular Therapies 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p>
<div class="lb-trans"><p>Intra-Cellular Therapies, Inc. 是一家生物制药公司，专注于小分子药物的发现、临床开发和商业化，这些药物主要针对神经精神和神经系统疾病的医疗需求，通过靶向中枢神经系统（CNS）中的细胞内信号机制。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Intra-Cellular Therapies</li>
<li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li>
<li>Options Activity Points to More Volatility for Palantir Stock</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>MicroStrategy Sees Insider Buy-Sell Action in Q1</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Intra-Cellular Therapies</li>
<li>股票中的缺口上涨意味着什么？如何操作缺口</li>
<li>期权活动指向 Palantir 股票的更多波动性</li>
<li>选举股票：选举如何影响股市</li>
<li>NVIDIA 股票：被低估，超卖——能跌到多低？</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>MicroStrategy 在第一季度看到内部买卖活动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ITCI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Intra-Cellular Therapies 吗？</h2>
</div><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Intra-Cellular Therapies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Intra-Cellular Therapies 并不在名单上。</p>
</div><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intra-Cellular Therapies 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fmr LLC 减少了在 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) 的持股